Monoclonal Antibodies

A wide variety of platforms are now available to make monoclonal antibodies and they currently represent an important part of the therapeutics on the market (Fig. 17.3b). They have an advantage over other therapeutic proteins in that their physico-chemical and phar-macokinetic properties are generally similar - allowing rapid production of material and a relatively streamlined approach to preclinical and early clinical testing. For the genome era proteins, one example is the antiBAFF antibody [Lymphostat-B (belimumab)] used for the treatment of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Antibodies against other emerging targets (targets after 1995) are currently under clinical development in many companies - we are currently developing anti-IL-31 and anti-IL-22Ra antibodies for use in dermatological indications.

Was this article helpful?

0 0
Natural Arthritis Relief

Natural Arthritis Relief

Natural Arthritis Relief details a unique method of reversing Rheumatoid Arthritis Symptoms by removing numerous arthritis triggers as well as toxins using a simple 5 step natural process.

Get My Free Ebook


Post a comment